MicroRNA in localized scleroderma: a review of literature

Wolska-Gawron, Katarzyna; Bartosińska, Joanna; Krasowska, Dorota

doi:10.1007/s00403-019-01991-0

Cited by 30 publications

(30 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the light of previous studies, miRNA-155 and miRNA-483 are profibrotic miRNAs with increased serum level in patients with LoSc, whereas miRNA-7, let-7, and miRNA-196a stand for antifibrotic ones with downregulated expression [10][11][12][13][14][15] . The authors have not found any significant correlations between the serum level and expression levels of the aforementioned miRNAs and severity and clinical symptoms of LoSc and some laboratory parameters [10][11][12][13][14] .…”

Section: Resultsmentioning

confidence: 89%

“…Liu et al reported that miRNA-223 mimics enhanced cell proliferation and production of collagen I, collagen III, α-SMA (alpha-smooth muscle actin) in cultured cardiac fibroblasts 20 . α-SMA is overproduced by fibroblasts and pointed out to be an indicator of myofibroblast differentiation 15 . Both persistent fibroblast proliferation and differentiation into myofibroblasts result in ECM synthesis and deposition-a crucial point in the pathogenesis of LoSc 15 .…”

Section: Resultsmentioning

confidence: 99%

“…α-SMA is overproduced by fibroblasts and pointed out to be an indicator of myofibroblast differentiation 15 . Both persistent fibroblast proliferation and differentiation into myofibroblasts result in ECM synthesis and deposition-a crucial point in the pathogenesis of LoSc 15 .…”

Section: Resultsmentioning

confidence: 99%

“…Results of current studies provide little evidence on the role of miRNA in LoSc. To the best of our knowledge, the expression levels of 5 miRNA (miRNA-155 and miRNA-483 miRNA-7, let-7, miRNA-196a) have been evaluated thus far in LoSc patients [10][11][12][13][14][15] . The aim of our study was to delineate miRNAs that may serve as biomarkers of LoSc, as well as to correlate the serum levels of the selected miRNAs with the severity and clinical symptoms of LoSc and some laboratory parameters.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Circulating miRNA-181b-5p, miRNA-223-3p, miRNA-210-3p, let 7i-5p, miRNA-21-5p and miRNA-29a-3p in patients with localized scleroderma as potential biomarkers

Wolska-Gawron

Bartosińska

Rusek

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

Localized scleroderma (LoSc) is a rare disease manifested by an inflammation and sclerosis of the skin. The latest studies focused on glycoprotein Krebs von den Lungen-6, surfactant protein-D, chemokine ligand 18 and dipeptidylpeptidase 4 as potential biomarkers of skin fibrosis in systemic scleroderma. Our study aimed to identify 6 miRNAs with elevated or decreased levels in 38 LoSc patients (31 females, 7 males) compared to healthy volunteers (HVs) and to correlate the selected miRNAs’ serum levels with the severity and the clinical symptoms of LoSc and some laboratory parameters with the selected miRNAs’ serum levels. The serum levels of miRNAs, i.e. miRNA-181b-5p, miRNA-223-3p, miRNA-21-5p, let 7i-5p, miRNA-29a-3p and miRNA-210-3p were significantly increased in the LoSc patients compared to the HVs. The level of let-7i increase in the female LoSc patients correlated negatively with BSA (r = − 0.355, p = 0.049) and mLoSSI (r = − 0.432, p = 0.015). Moreover, the female patients with inactive LoSc had significantly higher level of let-7i (2.68-fold on average) in comparison to those with active disease (p = 0.045). The exact role of those molecules has not been revealed in LoSc and a long-term longitudinal research is pivotal to confirm their prognostic value.

show abstract

Section: Resultsmentioning

confidence: 89%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Circulating miRNA-181b-5p, miRNA-223-3p, miRNA-210-3p, let 7i-5p, miRNA-21-5p and miRNA-29a-3p in patients with localized scleroderma as potential biomarkers

Wolska-Gawron

Bartosińska

Rusek

et al. 2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…The etiopathogenesis of LoS has not been fully understood. It is hypothesized to arise as a result of interactions between genetic, epigenetic, environmental, and immunological factors [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Laser Therapy for the Treatment of Morphea: A Systematic Review of Literature

Szczepanik-Kułak

Michalska-Jakubus

Krasowska

2021

JCM

Self Cite

View full text Add to dashboard Cite

Morphea, also known as localized scleroderma (LoS), comprises a set of autoimmune sclerotic skin diseases. It is characterized by inflammation and limited thickening and induration of the skin; however, in some cases, deeper tissues might also be involved. Although morphea is not considered a life-threatening disease, the apparent cosmetic disfigurement, functional or psychosocial impairment affects multiple fields of patients’ quality of life. Therapy for LoS is often unsatisfactory with numerous treatments that have only limited effectiveness or considerable side effects. Due to the advances in the application of lasers and their possible beneficial effects, the aim of this study is to review the reported usage of laser in morphea. We present a systematic review of available literature, performed with MEDLINE, Cinahl, Central, Scopus, Web of Science, and Google Scholar databases. We identified a total of twenty relevant studies (MEDLINE n = 10, Cinahl n = 1, Central n = 0, Scopus n = 2, Web of Science n = 5, Google Scholar n = 2) using laser therapy for LoS. Eight studies were focused on the use of PDL, six on fractional lasers (CO2 and Er:YAG), four on excimer, and two on either alexandrite or Nd:YAG.

show abstract

Morphoea and Allied Scarring and Sclerosing Inflammatory Dermatoses

Orteu

2024

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

MicroRNA in localized scleroderma: a review of literature

Abstract: Localized scleroderma (LoSc)

Cited by 30 publications

References 33 publications

Circulating miRNA-181b-5p, miRNA-223-3p, miRNA-210-3p, let 7i-5p, miRNA-21-5p and miRNA-29a-3p in patients with localized scleroderma as potential biomarkers

Circulating miRNA-181b-5p, miRNA-223-3p, miRNA-210-3p, let 7i-5p, miRNA-21-5p and miRNA-29a-3p in patients with localized scleroderma as potential biomarkers

Laser Therapy for the Treatment of Morphea: A Systematic Review of Literature

Morphoea and Allied Scarring and Sclerosing Inflammatory Dermatoses

Contact Info

Product

Resources

About